Format

Send to

Choose Destination
Clin Transplant. 2019 Apr 19:e13564. doi: 10.1111/ctr.13564. [Epub ahead of print]

Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in Solid Organ Transplant Recipients: Guidelines from the American Society of Transplantation Community of Practice.

Author information

1
Department of Medicine, University of Chicago, Chicago, Il.
2
Department of Medicine, Washington University School of Medicine, St. Louis, MO.

Abstract

These updated guidelines from the American Society of Transplantation Infectious Diseases Community of Practice address the prevention and management of Clostridium difficile infection in solid organ transplant (SOT) recipients. Clostridioides (formerly Clostridium) difficile infection (CDI) is among the most common hospital acquired infections. In SOT recipients the incidence of CDI varies by type and number or organs transplanted. While a meta-analysis of published literature found the prevalence of post-operative CDI in the general surgical population to be approximately 0.51%, the prevalence of CDI that is seen in the solid organ transplant population ranges from a low of 3.2% in the pancreatic transplant population to 12.7% in those receiving multiple organ transplants. There are no randomized, controlled trials evaluating the management of CDI in the SOT population. Herein is a review and summary of the currently available literature that has been synthesized into updated treatment guidelines for the management of CDI in the SOT population. This article is protected by copyright. All rights reserved.

KEYWORDS:

Clostridium difficile ; Antibiotic-associated diarrhea; nosocomial infection; pseudomembranous colitis; solid-organ transplant

PMID:
31002420
DOI:
10.1111/ctr.13564

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center